AbbVie’s rumored $1 billion acquisition of Gilgamesh Pharmaceuticals has amplified attention on the psychedelic therapeutics sector. Stocks of companies like Cybin, Mind Medicine, and GH Research have surged, driven by investor excitement over the promise of psychedelics in treating mental health disorders.
But while traditional psychedelic developers dominate headlines, Enveric Biosciences (NASDAQ: ENVB) has stayed quietly in the background, focusing on an equally groundbreaking, but less flashy, approach: non-hallucinogenic neuroplastogens, small molecules designed to promote neuroplasticity without psychoactive effects. This path represents a major leap forward in making psychedelic-like benefits practical, scalable, and clinically accessible.
